METABOLISM OF ASPIRIN AFTER THERAPEUTIC AND TOXIC DOSES

被引:19
作者
PATEL, DK
HESSE, A
OGUNBONA, A
NOTARIANNI, LJ
BENNETT, PN
机构
[1] ROYAL UNITED HOSP BATH,CLIN PHARMACOL UNIT,COMBE PARK,BATH BA1 3NG,ENGLAND
[2] BURROUGHS WELLCOME CO,DEPT MED BIOCHEM,RES TRIANGLE PK,NC 27709
[3] UNIV IFE,FAC PHARM,DEPT PHARMACEUT CHEM,ILE IFE,WILTS,NIGERIA
[4] UNIV GHANA,SCH MED,DEPT MED,ACCRA,GHANA
[5] UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1990年 / 9卷 / 03期
关键词
D O I
10.1177/096032719000900302
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 The urinary recovery of metabolites of aspirin (ASA) was studied in 45 volunteers who took a therapeutic dose (600 mg) of ASA by mouth and in 37 patients who took ASA in overdose. 2 The main metabolite recovered from the volunteers was the glycine conjugate, salicyluric acid (SUA), which accounted for 75.01 ± 1.19% of total urinary metabolites, whereas salicylic acid (SA) accounted for 8.82 ± 0.56%. Recovery of SUA was negatively correlated with that of S.A. (r = −0.8625, P < 0.001). 3 In 24 patients with admission plasma salicylate concentrations of 240-360 mg 1-1, SUA accounted for 46.66 ± 3.22% and S.A. for 31.88 ± 4.02%. 4 In 13 patients with admission plasma salicylate concentrations of 715-870 mg 1-1, SUA accounted for 21.57 ± 3.65% and S.A. for 64.72 ± 4.82%. 5 Reduced excretion of salicylate as SUA was also accompanied by increased elimination as gentisic acid and salicylic acid phenolic glucuronide indicating that the unsaturated processes that lead to the formation of these metabolites contribute significantly (22-23%) to the inactivation of large doses of salicylate. 6 While the Michalis-Menten kinetics of ASA have been well demonstrated at lower doses, our findings illustrate the progressive saturation of SUA formation under conditions of increasing ASA load to toxic amounts and raise issues about the in-vivo glycine pool when ASA is taken in overdose. © 1990, Sage Publications. All rights reserved.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 34 条
  • [1] ALI B, 1983, J PHARMACOL EXP THER, V226, P589
  • [2] A KINETIC STUDY OF ELIMINATION OF SALICYLATE IN MAN
    BEDFORD, C
    CUMMINGS, AJ
    MARTIN, BK
    [J]. BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1965, 24 (02): : 418 - &
  • [3] SALICYL PHENOLIC GLUCURONIDE PHARMACOKINETICS IN PATIENTS WITH RHEUMATOID-ARTHRITIS
    BOCHNER, F
    GRAHAM, GG
    POLVERINO, A
    IMHOFF, DM
    TREGENZA, RA
    ROLAN, PE
    CLELAND, LG
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (02) : 153 - 158
  • [4] SALICYLATE METABOLITE KINETICS AFTER SEVERAL SALICYLATES
    BOCHNER, F
    GRAHAM, GG
    CHAM, BE
    IMHOFF, DM
    HAAVISTO, TM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) : 266 - 275
  • [5] INTER-INDIVIDUAL DIFFERENCES IN THE GLYCINE CONJUGATION OF SALICYLIC-ACID
    CALDWELL, J
    OGORMAN, J
    SMITH, RL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (01) : P114 - P114
  • [6] CHAM BE, 1980, CLIN CHEM, V26, P111
  • [7] IDENTIFICATION AND PARTIAL-PURIFICATION OF THE MAJOR ASPIRIN HYDROLYZING ENZYME IN HUMAN-BLOOD
    COSTELLO, PB
    GREEN, FA
    [J]. ARTHRITIS AND RHEUMATISM, 1983, 26 (04): : 541 - 547
  • [8] COSTELLO PB, 1984, ARTHRITIS RHEUM, V26, P422
  • [9] FORMAN WB, 1971, MOL PHARMACOL, V7, P247
  • [10] SALICYLATE METABOLISM IN TWINS - EVIDENCE SUGGESTING A GENETIC INFLUENCE AND INDUCTION OF SALICYLURATE FORMATION
    FURST, DE
    GUPTA, N
    PAULUS, HE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (01) : 32 - 42